Formosa Laboratories Inc (4746) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Formosa Laboratories Inc (4746) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$276.59 Million ≈ $8.71 Million USD) by net assets (NT$8.56 Billion ≈ $269.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Formosa Laboratories Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Formosa Laboratories Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Formosa Laboratories Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formosa Laboratories Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HomeChoice Investments Ltd
JSE:HIL
|
-0.138x |
|
Yungjin Pharm Co Ltd
KO:003520
|
0.078x |
|
Nippon Indosari Corpindo Tbk
JK:ROTI
|
0.047x |
|
Remedy Entertainment Oyj
HE:REMEDY
|
0.139x |
|
Saksoft Limited
NSE:SAKSOFT
|
0.099x |
|
Map Boga Adiperkasa Tbk PT
JK:MAPB
|
0.066x |
|
Taiwan Fu Hsing Industrial Co Ltd
TW:9924
|
0.009x |
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
0.000x |
Annual Cash Flow Conversion Efficiency for Formosa Laboratories Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Formosa Laboratories Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Formosa Laboratories Inc (4746) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$8.65 Billion ≈ $272.42 Million |
NT$726.33 Million ≈ $22.88 Million |
0.084x | -16.57% |
| 2023-12-31 | NT$8.21 Billion ≈ $258.67 Million |
NT$826.60 Million ≈ $26.04 Million |
0.101x | +22.06% |
| 2022-12-31 | NT$7.80 Billion ≈ $245.63 Million |
NT$643.09 Million ≈ $20.26 Million |
0.082x | +101.53% |
| 2021-12-31 | NT$7.60 Billion ≈ $239.51 Million |
NT$311.16 Million ≈ $9.80 Million |
0.041x | -54.45% |
| 2020-12-31 | NT$5.29 Billion ≈ $166.53 Million |
NT$475.00 Million ≈ $14.97 Million |
0.090x | +38.16% |
| 2019-12-31 | NT$4.46 Billion ≈ $140.43 Million |
NT$289.92 Million ≈ $9.13 Million |
0.065x | +466.48% |
| 2018-12-31 | NT$4.56 Billion ≈ $143.60 Million |
NT$-80.89 Million ≈ $-2.55 Million |
-0.018x | -118.41% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.20 Million |
NT$395.42 Million ≈ $12.46 Million |
0.096x | -64.36% |
| 2016-12-31 | NT$4.10 Billion ≈ $129.29 Million |
NT$1.11 Billion ≈ $34.97 Million |
0.271x | +267.07% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.08 Million |
NT$255.15 Million ≈ $8.04 Million |
0.074x | -20.23% |
| 2014-12-31 | NT$3.04 Billion ≈ $95.63 Million |
NT$280.41 Million ≈ $8.83 Million |
0.092x | +620.58% |
| 2013-12-31 | NT$2.52 Billion ≈ $79.26 Million |
NT$32.25 Million ≈ $1.02 Million |
0.013x | -87.46% |
| 2012-12-31 | NT$1.67 Billion ≈ $52.75 Million |
NT$171.13 Million ≈ $5.39 Million |
0.102x | +1810.84% |
| 2011-12-31 | NT$1.88 Billion ≈ $59.23 Million |
NT$-11.23 Million ≈ $-353.84K |
-0.006x | -108.35% |
| 2010-12-31 | NT$1.39 Billion ≈ $43.90 Million |
NT$99.67 Million ≈ $3.14 Million |
0.072x | -79.01% |
| 2009-12-31 | NT$1.33 Billion ≈ $41.98 Million |
NT$454.22 Million ≈ $14.31 Million |
0.341x | -- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulator… Read more